Search results
Aug 23, 2022 · Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children ages 6 months through 4 years The vaccine efficacy remained consistently above 70% in both the 6 through 23 months and the 2 through 4 years age groups Sequencing of observed COVID-19 cases confirmed majority were caused by Omicron BA.2, broadening the evidence for efficacy across COVID-19 variants Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX ...
Dec 10, 2020 · BioNTech was the sponsor of the trial, manufactured the BNT162b2 clinical trial material, and contributed to the interpretation of the data and the writing of the manuscript. All the trial data ...
Oct 21, 2021 · The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.
Oct 15, 2021 · BioNTech, a German immunotherapy company, had pioneered a new genetic technology that uses a wisp of genetic code from a virus—called messenger RNA—to prompt cells to make antibodies that fight off that virus. 4 For decades, scientists had been working on similar concepts but frequently met defeat because of issues related to the structure and stability of the mRNA. 5 By using something called lipid nanoparticles, BioNTech was having success with stabilizing the mRNA 6, and by the time ...
Dec 11, 2020 · Pfizer and BioNTech are confident in their ability to deliver the vaccine to people in the U.S. Based on current projections, Pfizer’s and BioNTech’s combined manufacturing network has the potential to supply globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021 (subject to manufacturing capacity and regulatory approval or authorization).
Dec 9, 2022 · Pfizer-BioNTech COVID-19 Vaccine, Bivalent, (Original and Omicron BA.4/BA.5) AUTHORIZED USE . Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is FDA authorized under Emergency Use Authorization (EUA) for use in individuals 5 years of age and older as a single booster dose administered at least 2 months after either:
Sep 22, 2021 · Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA for individuals 16 years of age and older. The authorization was expanded on May 10, 2021 to include those 12 ...
